Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation

Leukemia Research

Volumn 37, Issue 9, 2013, Pages 1046-1051

  Zhu, Xiaoli ^a   Lai, Xiaoyu ^a   Luo, Yi ^a   Shi, Jimin ^a   Tan, Yamin ^a   Zheng, Weiyan ^a   He, Jingsong ^a   Xie, Wanzhuo ^a   Li, Li ^a   Zhang, Jie ^a   Ye, Xiujin ^a   Lin, Maofang ^a   Cai, Zhen ^a   Huang, He ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Allogeneic stem cell transplantation; GVHD; Mycophenolate mofetil; Unrelated donor

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GRAFT FAILURE; HLA MATCHING; HUMAN; HUMAN CELL; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPHYLAXIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; SCHOOL CHILD; TREATMENT OUTCOME; UNRELATED DONORS;

ALLOGENEIC STEM CELL TRANSPLANTATION; GVHD; MYCOPHENOLATE MOFETIL; UNRELATED DONOR;

ADOLESCENT; ADULT; CHILD; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; MORBIDITY; MYCOPHENOLIC ACID; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS; YOUNG ADULT;

EID: 84880961116     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.06.016     Document Type: Article

References (36)

1. Weisdorf D. Graft vs. host disease: pathology, prophylaxis and therapy: GVHD overview. Best Pract Res Clin Haematol 2008, 21:99-100.
2. Nash R.A., Antin J.H., Karanes C., Fay J.W., Avalos B.R., Yeager A.M., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.
3. Ratanatharathorn V., Nash R.A., Przepiorka D., Devine S.M., Klein J.L., Weisdorf D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998, 92:2303-2314.
4. Bolaños-Meade J. Update on the management of acute graft-versus-host disease. Curr Opin Oncol 2006, 18:120-125.
5. Devergie A., Apperley J.F., Labopin M., Madrigal A., Jacobsen N., Carreras E., et al. European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997, 20:11-19.
6. Sun Y., Tawara I., Toubai T., Reddy P. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res 2007, 150:197-214.
7. Ho V.T., Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001, 98:3192-3204.
8. Lee S.J., Zahrieh D., Alyea E.P., Weller E., Ho V.T., Antin J.H., et al. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood 2002, 100:2697-2702.
9. Storb R., Antin J.H., Cutler C. Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?. Biol Blood Marrow Transplant 2010, 16:S18-S27.
10. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 2005, 35:225-231.
11. Finke J., Bethge W.A., Schmoor C., Ottinger H.D., Stelljes M., Zander A.R., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
12. Yu C., Seidel K., Nash R.A., Deeg H.J., Sandmaier B.M., Barsoukov A., et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 1998, 91:2581-2587.
13. Vogelsang G.B., Arai S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 2001, 27:1255-1262.
14. Kasper C., Sayer H.G., Mugge L.O., Schilling K., Scholl S., Issa M.C., et al. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors. Bone Marrow Transplant 2004, 33:65-69.
15. Nash R.A., Johnston L., Parker P., McCune J.S., Storer B., Slattery J.T., et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005, 11:495-505.
16. Piñana J.L., Valcárcel D., Fernández-Avilés F., Martino R., Rovira M., Barba P., et al. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant 2010, 45:1449-1456.
17. Zohren F., Schroeder T., Czibere A., Fenk R., Bruns I., Kondakci M., et al. Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases. Bone Marrow Transplant 2011, 46:747-755.
18. Schleuning M., Judith D., Jedlickova Z., Stübig T., Heshmat M., Baurmann H., et al. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transplant 2009, 43:717-723.
19. Huang H., Zheng W., Lin M., Fu J., Zhang R. Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation by mycophenolate mofetil in a murine model. Zhonghua Xue Ye Xue Za Zhi 2002, 23:191-193.
20. Przepiorka D., Weisdorf D., Martin P., Klingemann H.G., Beatty P., Hows J., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
21. Filipovich A.H., Weisdorf D., Pavletic S., Socie G., Wingard J.R., Lee S.J., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
22. Huang H., Lin M., Meng H., Qian W., Jin J., Huang J., et al. Combination of mycophenolate mofetil with cyclosporine A and methotrexate as acute GVHD prophylaxis after unrelated donor allogeneic bone marrow transplantation. Zhonghua Xue Ye Xue Za Zhi 2001, 22:76-78.
23. Lai Y., Ma J., Schwarzenberger P., Li W., Cai Z., Zhou J., et al. Combination of CsA, MTX and low-dose, short-course mycophenolate mofetil for GVHD prophylaxis. Bone Marrow Transplant 2009, 43:61-67.
24. Mohty M., Labopin M., Balère M.L., Socié G., Milpied N., Tabrizi R., et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire. Leukemia 2010, 24:1867-1874.
25. Wagner J.E., Thompson J.S., Carter S.L., Kernan N.A. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 2005, 366:733-741.
26. Hansen J.A., Gooley T.A., Martin P.J., Appelbaum F., Chauncey T.R., Clift R.A., et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998, 338:962-968.
27. Karanes C., Nelson G.O., Chitphakdithai P., Agura E., Ballen K.K., Bolan C.D., et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008, 14:8-15.
28. Shapira M., Hirshfeld E., Weiss L., Zeira M., Kasir J., Or R., et al. Mycophenolate mofetil does not suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model. Cancer Immunol Immunother 2005, 54:383-388.
29. Bullingham R., Monroe S., Nicholls A., Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clinl Pharmacol 1996, 36:315-324.
30. Bolwell B., Sobecks R., Pohlman B., Andresen S., Rybicki L., Kuczkowski E., et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004, 34:621-625.
31. Perkins J., Field T., Kim J., Kharfan-Dabaja M.A., Fernandez H., Ayala E., et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2010, 16:937-947.
32. Kaushik M., Kay M.D., Bagul A., Nicholson M.L. Morbidity rates with reduced mycophenolate mofetil dosage: a singlecenter experience. Transplant Proc 2006, 38:2864-2865.
33. Nishikawa S., Okamura A., Yamamori M., Minagawa K., Kawamori Y., Kawano Y., et al. Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease. Transplant Proc 2009, 41:3873-3876.
34. Mourad M., Malaise J., Chaib Eddour D., De Meyer M., König J., Schepers R., et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001, 47:88-94.
35. Vokurka S., Steinerova K., Karas M., Koza V. Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2. Bone Marrow Transplant 2009, 44:601-605.
36. Olsson R., Remberger M., Schaffer M., Berggren D.M., Svahn B.M., Mattsson J., et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant 2013, 48:537-543.